CERALASERTIB

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C20H24N6O2S
Molecular Weight	412.509
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C[C@@H]1COCCN1C2=NC(=NC(=C2)C3(CC3)[S@](C)(=N)=O)C4=CN=CC5=C4C=CN5

InChI

InChIKey=DTTJKLNXNZAVSM-JYCIKRDWSA-N

InChI=1S/C20H24N6O2S/c1-13-12-28-8-7-26(13)18-9-17(20(4-5-20)29(2,21)27)24-19(25-18)15-10-22-11-16-14(15)3-6-23-16/h3,6,9-11,13,21,23H,4-5,7-8,12H2,1-2H3/t13-,29-/m1/s1

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28138034 | https://clinicaltrials.gov/ct2/show/NCT03334617 | https://clinicaltrials.gov/ct2/show/NCT03787680 | https://clinicaltrials.gov/ct2/show/NCT03780608

Ceralasertib, previously known as AZD6738, a potent and selective inhibitor of ataxia telangiectasia and Rad3-related (ATR) kinase was developed as an anticancer agent. Prevention of ATR-mediated signaling leads to the inhibition of DNA damage checkpoint activation, disruption of DNA damage repair, and the induction of tumor cell apoptosis. AZD6738 as a combination therapy participates in phase II clinical trials for the treatment of gastric adenocarcinoma and malignant melanoma (in combination with durvalumab). For the treatment of gastric and breast cancer in combination with carboplatin, or with olaparib or with MEDI4736. Combination of acalabrutinib and AZ6738 is used in phase II trials for patients with chronic lymphocytic Leukemia. Besides, AZD6738 participates in umbrella Phase II study in patients with metastatic non-small cell lung cancer (NSCLC) who have progressed on an anti-programmed cell death-1/anti-programmed cell death ligand 1 (anti-PD-1/PD-L1) containing therapy.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Serine-protein kinase ATR 5 Target ID: CHEMBL5024 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26517239\|https://openinnovation.astrazeneca.com/azd6738.html	Inhibitor 8297		1.0 nM [IC50]

PubMed

Title	Date	PubMed
The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo.	2015 Dec 29	26517239
AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells.	2017 Apr	28138034
Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent.	2018 Nov 21	30346772

Sample Use Guides

In Vivo Use Guide

AZD6738 will be administered at 240 mg twice daily on days 1 to 7 in Cycle 0 (lead-in period) and therafter at 240 mg BD on days 22 to 28 in a 28-day cycle.

Route of Administration: Oral

Name

Type

Language

CERALASERTIB

Official Name

English

ATR KINASE INHIBITOR AZD6738

Common Name

English

4-[4-[1-[[S(R)]-S-Methylsulfonimidoyl]cyclopropyl]-6-[(3R)-3-methyl-4-morpholinyl]-2-pyrimidinyl]-1H-pyrrolo[2,3-b]pyridine

Systematic Name

English

AZD-6738

Common Name

English

CERALASERTIB [USAN]

Common Name

English

ceralasertib [INN]

Common Name

English

Ceralasertib [WHO-DD]

Common Name

English

1H-PYRROLO(2,3-B)PYRIDINE, 4-(4-(1-((S(R))-S-METHYLSULFONIMIDOYL)CYCLOPROPYL)-6-((3R)-3-METHYL-4-MORPHOLINYL)-2-PYRIMIDINYL)-

Systematic Name

English

AZD6738

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C155926